Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × mirvetuximab soravtansine × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3 Tumor-Agnostic 1

Conditions

Interventions

Surveys and Questionnaires 53 pembrolizumab 48 Gemcitabine 47 Paclitaxel 46 Carboplatin 40 Blood Specimen Collection 40 Bevacizumab 36 Docetaxel 31 Fluorouracil 29 Cisplatin 29 Nivolumab 27 Capecitabine 26 Standard of Care 23 Irinotecan 22 Radiotherapy 21 Pemetrexed 21 Interviews as Topic 21 Magnetic Resonance Spectroscopy 20 Leucovorin 20 Erlotinib Hydrochloride 20 Oxaliplatin 18 Cetuximab 18 Afatinib 17 atezolizumab 16 Sorafenib 15 Methods 14 Cyclophosphamide 14 trametinib 13 olaparib 13 Ipilimumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01609556 2021-02-17

IMGN853-0401

ImmunoGen, Inc.

Phase 1 Completed

206 enrolled 46 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡